ORIGINAL RESEARCH
Published on 22 Oct 2024
Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study
doi 10.3389/fimmu.2024.1422784
- 482 views